Effects of Pravastatin on Cholesterol, Inflammation and Cognition in Schizophrenia

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia, Schizoaffective Disorders, Schizophreniform Disorders

In brief

This study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. Some antipsychotic medications may cause an increase in cholesterol levels, which may lead to inflammation in the body. Inflammation poses a risk in developing heart disease, diabetes and problems with brain function. The purpose of this study is to see if pravastatin can: * Lower cholesterol * Decrease inflammation * Improve cognition in patients with schizophrenia

Key facts

Study ID
NCT01082588
Run by
Massachusetts General Hospital
People needed
60
Starts
2010-06-01
Expected to finish
2012-09-01
Last updated by the study team
2014-04-28

Who can join

Age: 18 and older, up to 68. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.